283 related articles for article (PubMed ID: 19248640)
1. [Phamacoeconomic analysis of antibiotics use in the Clinical Center of Vojvodina].
Stefan-Mikić S; Jovanović J; Jovanović N; Aleksić-Dordević M; Cvjetković D; Krajcir I
Med Pregl; 2008; 61 Suppl 1():50-8. PubMed ID: 19248640
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacoeconomical analysis of antibiotic use at the Clinic For Infectious Diseases of the Clinical Center of Vojvodina].
Stefan-Mikić S; Jovanović J; Jovanović N; Sević S; Vukadinov J; Miucin-Vukadinović I
Med Pregl; 2008; 61 Suppl 1():40-9. PubMed ID: 19248639
[TBL] [Abstract][Full Text] [Related]
3. [The choice of antimicrobial therapy by application of pharmacoeconomic principles in view of the most frequently isolated pathogens at the Clinic for Infectious Diseases of the Clinical Center of Vojvodina].
Stefan-Mikić S; Sević S; Jovanović N; Cvjetković D; Aleksić-Dordević M
Med Pregl; 2010; 63 Suppl 1():52-9. PubMed ID: 21438205
[TBL] [Abstract][Full Text] [Related]
4. [The choice of antimicrobial therapy in view of the most frequently isolated pathogens at the Insitute Of Surgery in the Clinical Center of Vojvodina].
Sabo A; Tomić Z; Stefan-Mikić S; Sević S; Horvat O; Milijasević B
Med Pregl; 2008; 61 Suppl 1():31-9. PubMed ID: 19256066
[TBL] [Abstract][Full Text] [Related]
5. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II.
Kusowska J
Acta Pol Pharm; 2005; 62(6):491-5. PubMed ID: 16583990
[TBL] [Abstract][Full Text] [Related]
6. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I.
Kusowska J
Acta Pol Pharm; 2005; 62(6):485-90. PubMed ID: 16583989
[TBL] [Abstract][Full Text] [Related]
7. The effect of limiting antimicrobial therapy duration on antimicrobial resistance in the critical care setting.
Marra AR; de Almeida SM; Correa L; Silva M; Martino MD; Silva CV; Cal RG; Edmond MB; dos Santos OF
Am J Infect Control; 2009 Apr; 37(3):204-9. PubMed ID: 18986735
[TBL] [Abstract][Full Text] [Related]
8. [Antibiotic pharmacoeconomics].
Jahnz-Rózyk K
Pol Merkur Lekarski; 2008 Nov; 25(149):437-8. PubMed ID: 19177784
[TBL] [Abstract][Full Text] [Related]
9. How to fight antimicrobial resistance.
Foucault C; Brouqui P
FEMS Immunol Med Microbiol; 2007 Mar; 49(2):173-83. PubMed ID: 17181560
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacoeconomics of infection in the intensive care unit].
Grau S; Alvarez-Lerma F
Rev Esp Quimioter; 2008; 21 Spec No 1():26-34. PubMed ID: 18752077
[TBL] [Abstract][Full Text] [Related]
11. Changes in antibiotic use, cost and consumption after an antibiotic restriction policy applied by infectious disease specialists.
Ozkurt Z; Erol S; Kadanali A; Ertek M; Ozden K; Tasyaran MA
Jpn J Infect Dis; 2005 Dec; 58(6):338-43. PubMed ID: 16377863
[TBL] [Abstract][Full Text] [Related]
12. [Modifiability of antibiotic use in a medical clinic].
Bögli F; Pechula M; Mühlebach S; Conen D
Schweiz Med Wochenschr; 1996 Nov; 126(48):2078-81. PubMed ID: 8992628
[TBL] [Abstract][Full Text] [Related]
13. The crisis of antibiotic-resistance in bacteria.
El-Tahawy AT
Saudi Med J; 2004 Jul; 25(7):837-42. PubMed ID: 15235684
[TBL] [Abstract][Full Text] [Related]
14. Economics of antibiotic resistance.
Sipahi OR
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):523-39. PubMed ID: 18662118
[TBL] [Abstract][Full Text] [Related]
15. [Clinical effectiveness and costs of antibiotics in respiratory infections].
Jahnz-Rózyk K
Pol Merkur Lekarski; 2011 May; 30(179):327-9. PubMed ID: 21675134
[TBL] [Abstract][Full Text] [Related]
16. Future pharmacoeconomic criteria for the treatment of infections.
Milkovich G
Int J Antimicrob Agents; 2009 Jul; 34 Suppl 1():S12-4. PubMed ID: 19560668
[TBL] [Abstract][Full Text] [Related]
17. Balancing the benefits and costs of antibiotic drugs: the TREAT model.
Leibovici L; Paul M; Andreassen S
Clin Microbiol Infect; 2010 Dec; 16(12):1736-9. PubMed ID: 20673259
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact and relevance of antibiotic resistance.
French GL
Adv Drug Deliv Rev; 2005 Jul; 57(10):1514-27. PubMed ID: 15978698
[TBL] [Abstract][Full Text] [Related]
19. [Strategy for empirical antibiotic therapy re-evaluation: do you have to change a successful therapy?].
Veber B
Ann Fr Anesth Reanim; 2004 Jun; 23(6):654-7. PubMed ID: 15234739
[No Abstract] [Full Text] [Related]
20. Activity and impact on antibiotic use and costs of a dedicated infectious diseases consultant on a septic orthopaedic unit.
Uçkay I; Vernaz-Hegi N; Harbarth S; Stern R; Legout L; Vauthey L; Ferry T; Lübbeke A; Assal M; Lew D; Hoffmeyer P; Bernard L
J Infect; 2009 Mar; 58(3):205-12. PubMed ID: 19232739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
